NCT03523572: Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have tumors that are either HER2+ (IHC 3+) or HER2-low (defined as IHC 1+ or 2+ & ISH-negative)
Exclusions: Patients with prior treatment with nivolumab or DS-8201a (Enhertu)

Comments are closed.

Up ↑